Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia

Cecilia Evangelisti, Alessandra Cappellini, Mariana Oliveira, Rita Fragoso, João T. Barata, Alice Bertaina, Franco Locatelli, Carolina Simioni, Luca M. Neri, Francesca Chiarini, Annalisa Lonetti, Francesca Buontempo, Ester Orsini, Andrea Pession, Lucia Manzoli, Alberto Maria Martelli, Camilla Evangelisti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Despite remarkable progress in polychemotherapy protocols, pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains fatal in around 20% of cases. Hence, novel targeted therapies are needed for patients with poor prognosis. Glucocorticoids (GCs) are drugs commonly administrated for B-ALL treatment. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin signaling pathway is frequently observed in B-ALL and contributes to GC-resistance. Here, we analyzed for the first time to our knowledge, the therapeutic potential of pan and isoform-selective PI3K p110 inhibitors, alone or combined with dexamethasone (DEX), in B-ALL leukemia cell lines and patient samples. We found that a pan PI3K p110 inhibitor displayed the most powerful cytotoxic effects in B-ALL cells, by inducing cell cycle arrest and apoptosis. Both a pan PI3K p110 inhibitor and a dual γ/δ PI3K p110 inhibitor sensitized B-ALL cells to DEX by restoring nuclear translocation of the GC receptor and counteracted stroma-induced DEX-resistance. Finally, gene expression analysis documented that, on one hand the combination consisting of a pan PI3K p110 inhibitor and DEX strengthened the DEX-induced up- or down-regulation of several genes involved in apoptosis, while on the other, it rescued the effects of genes that might be involved in GC-resistance. Overall, our findings strongly suggest that PI3K p110 inhibition could be a promising strategy for treating B-ALL patients by improving GC therapeutic effects and/or overcoming GC-resistance.

Original languageEnglish
Pages (from-to)1796-1811
Number of pages16
JournalJournal of Cellular Physiology
Volume233
Issue number3
DOIs
Publication statusPublished - Aug 4 2017

Fingerprint

Phosphatidylinositol 3-Kinase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Glucocorticoids
B-Lymphocytes
Cells
Dexamethasone
Genes
Apoptosis
Pediatrics
Glucocorticoid Receptors
Therapeutic Uses
Sirolimus
Cell Cycle Checkpoints
Combination Drug Therapy
Gene expression
Protein Isoforms
Leukemia
Up-Regulation
Therapeutics
Down-Regulation

Keywords

  • ALL
  • dexamethasone
  • PI3K inhibitors
  • targeted therapy

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. / Evangelisti, Cecilia; Cappellini, Alessandra; Oliveira, Mariana; Fragoso, Rita; Barata, João T.; Bertaina, Alice; Locatelli, Franco; Simioni, Carolina; Neri, Luca M.; Chiarini, Francesca; Lonetti, Annalisa; Buontempo, Francesca; Orsini, Ester; Pession, Andrea; Manzoli, Lucia; Martelli, Alberto Maria; Evangelisti, Camilla.

In: Journal of Cellular Physiology, Vol. 233, No. 3, 04.08.2017, p. 1796-1811.

Research output: Contribution to journalArticle

Evangelisti, C, Cappellini, A, Oliveira, M, Fragoso, R, Barata, JT, Bertaina, A, Locatelli, F, Simioni, C, Neri, LM, Chiarini, F, Lonetti, A, Buontempo, F, Orsini, E, Pession, A, Manzoli, L, Martelli, AM & Evangelisti, C 2017, 'Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia', Journal of Cellular Physiology, vol. 233, no. 3, pp. 1796-1811. https://doi.org/10.1002/jcp.26135
Evangelisti, Cecilia ; Cappellini, Alessandra ; Oliveira, Mariana ; Fragoso, Rita ; Barata, João T. ; Bertaina, Alice ; Locatelli, Franco ; Simioni, Carolina ; Neri, Luca M. ; Chiarini, Francesca ; Lonetti, Annalisa ; Buontempo, Francesca ; Orsini, Ester ; Pession, Andrea ; Manzoli, Lucia ; Martelli, Alberto Maria ; Evangelisti, Camilla. / Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. In: Journal of Cellular Physiology. 2017 ; Vol. 233, No. 3. pp. 1796-1811.
@article{304bd2ab95924604a0ed10cffb7e81bd,
title = "Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia",
abstract = "Despite remarkable progress in polychemotherapy protocols, pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains fatal in around 20{\%} of cases. Hence, novel targeted therapies are needed for patients with poor prognosis. Glucocorticoids (GCs) are drugs commonly administrated for B-ALL treatment. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin signaling pathway is frequently observed in B-ALL and contributes to GC-resistance. Here, we analyzed for the first time to our knowledge, the therapeutic potential of pan and isoform-selective PI3K p110 inhibitors, alone or combined with dexamethasone (DEX), in B-ALL leukemia cell lines and patient samples. We found that a pan PI3K p110 inhibitor displayed the most powerful cytotoxic effects in B-ALL cells, by inducing cell cycle arrest and apoptosis. Both a pan PI3K p110 inhibitor and a dual γ/δ PI3K p110 inhibitor sensitized B-ALL cells to DEX by restoring nuclear translocation of the GC receptor and counteracted stroma-induced DEX-resistance. Finally, gene expression analysis documented that, on one hand the combination consisting of a pan PI3K p110 inhibitor and DEX strengthened the DEX-induced up- or down-regulation of several genes involved in apoptosis, while on the other, it rescued the effects of genes that might be involved in GC-resistance. Overall, our findings strongly suggest that PI3K p110 inhibition could be a promising strategy for treating B-ALL patients by improving GC therapeutic effects and/or overcoming GC-resistance.",
keywords = "ALL, dexamethasone, PI3K inhibitors, targeted therapy",
author = "Cecilia Evangelisti and Alessandra Cappellini and Mariana Oliveira and Rita Fragoso and Barata, {Jo{\~a}o T.} and Alice Bertaina and Franco Locatelli and Carolina Simioni and Neri, {Luca M.} and Francesca Chiarini and Annalisa Lonetti and Francesca Buontempo and Ester Orsini and Andrea Pession and Lucia Manzoli and Martelli, {Alberto Maria} and Camilla Evangelisti",
year = "2017",
month = "8",
day = "4",
doi = "10.1002/jcp.26135",
language = "English",
volume = "233",
pages = "1796--1811",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia

AU - Evangelisti, Cecilia

AU - Cappellini, Alessandra

AU - Oliveira, Mariana

AU - Fragoso, Rita

AU - Barata, João T.

AU - Bertaina, Alice

AU - Locatelli, Franco

AU - Simioni, Carolina

AU - Neri, Luca M.

AU - Chiarini, Francesca

AU - Lonetti, Annalisa

AU - Buontempo, Francesca

AU - Orsini, Ester

AU - Pession, Andrea

AU - Manzoli, Lucia

AU - Martelli, Alberto Maria

AU - Evangelisti, Camilla

PY - 2017/8/4

Y1 - 2017/8/4

N2 - Despite remarkable progress in polychemotherapy protocols, pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains fatal in around 20% of cases. Hence, novel targeted therapies are needed for patients with poor prognosis. Glucocorticoids (GCs) are drugs commonly administrated for B-ALL treatment. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin signaling pathway is frequently observed in B-ALL and contributes to GC-resistance. Here, we analyzed for the first time to our knowledge, the therapeutic potential of pan and isoform-selective PI3K p110 inhibitors, alone or combined with dexamethasone (DEX), in B-ALL leukemia cell lines and patient samples. We found that a pan PI3K p110 inhibitor displayed the most powerful cytotoxic effects in B-ALL cells, by inducing cell cycle arrest and apoptosis. Both a pan PI3K p110 inhibitor and a dual γ/δ PI3K p110 inhibitor sensitized B-ALL cells to DEX by restoring nuclear translocation of the GC receptor and counteracted stroma-induced DEX-resistance. Finally, gene expression analysis documented that, on one hand the combination consisting of a pan PI3K p110 inhibitor and DEX strengthened the DEX-induced up- or down-regulation of several genes involved in apoptosis, while on the other, it rescued the effects of genes that might be involved in GC-resistance. Overall, our findings strongly suggest that PI3K p110 inhibition could be a promising strategy for treating B-ALL patients by improving GC therapeutic effects and/or overcoming GC-resistance.

AB - Despite remarkable progress in polychemotherapy protocols, pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains fatal in around 20% of cases. Hence, novel targeted therapies are needed for patients with poor prognosis. Glucocorticoids (GCs) are drugs commonly administrated for B-ALL treatment. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin signaling pathway is frequently observed in B-ALL and contributes to GC-resistance. Here, we analyzed for the first time to our knowledge, the therapeutic potential of pan and isoform-selective PI3K p110 inhibitors, alone or combined with dexamethasone (DEX), in B-ALL leukemia cell lines and patient samples. We found that a pan PI3K p110 inhibitor displayed the most powerful cytotoxic effects in B-ALL cells, by inducing cell cycle arrest and apoptosis. Both a pan PI3K p110 inhibitor and a dual γ/δ PI3K p110 inhibitor sensitized B-ALL cells to DEX by restoring nuclear translocation of the GC receptor and counteracted stroma-induced DEX-resistance. Finally, gene expression analysis documented that, on one hand the combination consisting of a pan PI3K p110 inhibitor and DEX strengthened the DEX-induced up- or down-regulation of several genes involved in apoptosis, while on the other, it rescued the effects of genes that might be involved in GC-resistance. Overall, our findings strongly suggest that PI3K p110 inhibition could be a promising strategy for treating B-ALL patients by improving GC therapeutic effects and/or overcoming GC-resistance.

KW - ALL

KW - dexamethasone

KW - PI3K inhibitors

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85028947826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028947826&partnerID=8YFLogxK

U2 - 10.1002/jcp.26135

DO - 10.1002/jcp.26135

M3 - Article

C2 - 28777460

AN - SCOPUS:85028947826

VL - 233

SP - 1796

EP - 1811

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 3

ER -